LEGN · Legend Biotech Corporation American Depositary Shares
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow LEGN by emailGet an email when LEGN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LEGN, unsubscribe in one click. Privacy
📣 What LEGN Says Is Next
in 2026 · “Advanced early-stage cell therapy portfolio, with multiple data presentations expected at medical conferences in 2026”
Company press release, May 12, 2026 · SEC filing
2H 2026 · “Targeting multiple investigational new drug (IND) filings for oncology and autoimmune indications starting in 2H 2026.”
Company press release, Jan 12, 2026 · SEC filing
second half of 2026 · “First-in-human data expected starting in the second half of 2026.”
Company press release, Jan 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full LEGN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LEGN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.